Examkin

Soru

Zorluk: Çok zorImmunologic and Inflammatory Processes

A 48-year-old man presents to the transplant clinic with a rapidly rising serum creatinine (2.8 mg/dL, up from a baseline of 1.2 mg/dL) and oliguria 4 weeks after receiving a deceased-donor renal allograft. His current immunosuppressive regimen includes tacrolimus, mycophenolate mofetil, and prednisone. Trough tacrolimus levels are within the therapeutic target range, and medication adherence is confirmed. He is afebrile, and his blood pressure is 150/90 mmHg. Physical examination reveals mild tenderness over the allograft site in the right lower quadrant. Based on the suspected immunopathologic process, arrange the following diagnostic and therapeutic steps in the most appropriate chronological sequence for the definitive evaluation and management of this patient's condition.

  1. 1Perform Doppler ultrasonography of the renal allograft
  2. 2Perform an ultrasound-guided core needle biopsy of the renal allograft
  3. 3Evaluate the tissue specimen for peritubular capillary C4d deposition
  4. 4Initiate therapeutic plasma exchange (plasmapheresis)
  5. 5Administer intravenous immune globulin (IVIG) and rituximab

Cevap

The correct sequence is: 1) Perform Doppler ultrasonography, 2) Perform an ultrasound-guided core needle biopsy, 3) Evaluate for peritubular capillary C4d deposition, 4) Initiate therapeutic plasma exchange, 5) Administer IVIG and rituximab.
The evaluation of acute renal allograft dysfunction follows a strict algorithm. First, mechanical, urologic, and vascular issues are ruled out non-invasively with Doppler ultrasound. Once ruled out, the gold standard diagnostic test is an allograft biopsy. The biopsy must be evaluated with specialized immunohistochemical staining (C4d) to identify the footprint of complement activation, distinguishing antibody-mediated rejection (AMR) from acute cellular rejection. Once AMR is confirmed, the immunologic treatment sequence is critical: pre-formed pathogenic donor-specific antibodies must first be physically removed via plasmapheresis. Only AFTER plasmapheresis should biologic therapies like IVIG and rituximab be administered; if given before, the plasmapheresis circuit would simply extract the therapeutic antibodies from the patient's circulation.

Adım Adım Çözüm

1
Rule out structural or vascular etiologies
Doppler ultrasound confirms vascular patency and rules out hydronephrosis.
Anatomical complications must be excluded before attributing graft failure to an immunologic process or subjecting the patient to an invasive biopsy.
2
Obtain tissue for histopathologic and immunologic diagnosis
Core needle biopsy is successfully performed.
Tissue is required to distinguish between the cellular (T-cell mediated) and humoral (B-cell/antibody mediated) arms of the immune response, as treatments differ significantly.
3
Identify the precise immunopathologic mechanism
C4d staining is positive in peritubular capillaries.
C4d confirms classical complement cascade activation by donor-specific antibodies (DSAs), establishing the diagnosis of acute antibody-mediated rejection (AMR).
4
Acute clearance of circulating alloantibodies
Therapeutic plasma exchange physically removes the pathogenic antibodies.
Immediate cessation of the complement-mediated inflammatory damage to the allograft endothelium requires rapid reduction in circulating DSA titers.
5
Long-term suppression of the humoral immune response
IVIG and rituximab provide immunomodulation and B-cell depletion.
Preventing the rebound production of antibodies by targeting CD20+ B-cells ensures long-term graft survival after the initial plasma exchange.

Anahtar Kavram

The diagnostic differentiation and sequential therapeutic management of acute antibody-mediated rejection (AMR) in solid organ transplantation.
Bu soruyu puanla

Konular

Immunologic and Inflammatory Processes

Bu konudan daha fazla soru